Australia's Neuren jumps as partner sees Rett syndrome drug sales hitting $700 mln by 2028

Neuren Pharmaceuticals

14/01/2026 02:14

** Shares of Neuren Pharmaceuticals NEU.AX advances ~6% to A$20.47, set for its strongest session since August 27, 2025

** Co says partner Acadia Pharmaceuticals ACAD.O projected global net sales of its Rett syndrome treatment drug Daybue to hit $700 million by 2028

** Co receives royalties on net sales

** 402,437 shares traded, 1.7x the 30-day avg volume

** Stock gained 48.9% in 2025

 (Reporting by Kumar Tanishk in Bengaluru)

 ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))